← back to search

Daniela F. Quail

McGill University Health Centre · CA
Area of research
Immunology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Immune cells in cancer, Ferroptosis and cancer prognosis, Neutrophil, Myeloperoxidase and Oxidative Mechanisms, and Chromatin Remodeling and Cancer.
h-index
39
citations
19,851
works
148
NIH funding
primary concept
Medicine
email

Recent publications

Architecture of the neutrophil compartment.
2026cited by 5position: contributordoi
From complexity to consensus: A roadmap for neutrophil classification
Immunity 2025cited by 25position: middledoi
Spatially mapping the tumour immune microenvironments of non-small cell lung cancer.
2025cited by 21position: contributordoi
Architecture of the neutrophil compartment
Nature 2025cited by 17position: middledoi
A Dock8-dependent mechanosensitive central actin pool maintains T cell shape and protects the nucleus during migration.
2025cited by 8position: contributordoi
The impact of a high fat diet and platelet activation on pre-metastatic niche formation.
2025cited by 7position: contributordoi
Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer.
2025cited by 0position: contributordoi
Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer.
2024cited by 33position: contributordoi
Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function.
2024cited by 23position: contributordoi
Cancer Hallmarks: Piecing the Puzzle Together.
2024cited by 11position: contributordoi
Revolutionizing cancer research with spatial proteomics and visual intelligence.
2024cited by 10position: contributordoi
Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies.
2024cited by 10position: contributordoi
Breast Cancer Immunity: It is TIME for the Next Chapter.
2024cited by 4position: contributordoi
Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
2024cited by 1position: contributordoi
Data from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 1position: contributordoi
Data from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 1position: contributordoi
Supplementary Data from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S1 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S5 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S3 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S1 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S3 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S4 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S4 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Data from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Supplementary Data from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S2 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S2 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S1 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi
Table S3 from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 20 papers (2019–2025)Logan Walsh · Cancer Institute (WIA)12 papers (2019–2025)Thomas Walle · Deutschen Konsortium für Translationale Krebsforschung4 papers (2022–2023)Scott W. Lowe · Memorial Sloan Kettering Cancer Center4 papers (2022–2023)Andrew J. Dannenberg · BioVentures (United States)3 papers (2017–2021)Yuhong Wei · McGill University Health Centre3 papers (2021–2023) · 3 papers (2020–2023)Direna Alonso-Curbelo · Disco (Germany)3 papers (2022–2024)Miranda W. Yu · McGill University3 papers (2023–2025)Direna Alonso‐Curbelo · Institute for Research in Biomedicine2 papers (2022–2023)Chujun Zhao · Columbia University2 papers (2022–2023)Erik R. Nelson · University of Illinois Urbana-Champaign2 papers (2020–2020)Zhen Zhao · Cold Spring Harbor Laboratory2 papers (2022–2023)Alexandra Wuest · Massachusetts Institute of Technology2 papers (2022–2023)Zi-Ning Choo · Cornell University2 papers (2022–2023)Graeme J. Koelwyn · University of British Columbia2 papers (2017–2020)Kathryn J. Moore · NYU Langone Health2 papers (2020–2020)Ignas Masilionis · Motlow State Community College2 papers (2022–2023)Yubin Xie · Weill Cornell Medicine2 papers (2022–2023)Francisco M. Barriga · Centro de Investigación Biomédica en Red de Cáncer2 papers (2022–2023)